Human Genetics

, Volume 131, Issue 3, pp 317–323

The genetics of kidney transplantation

Review Paper


Over the last decade, the search for gene variants with the potential to influence transplant outcomes or predispose individuals to host–recipient-related phenotypes has generated a considerable number of studies with conflicting results. Thousands of genotypes have been associated with complex traits related to transplant medicine, including acute rejection, immunosuppressive drug metabolism and side effects, infections, long-term outcomes, and cardiovascular complications. However, these efforts have given disappointing results, both in terms of gaining understanding of the biological basis of disease and in patient management. The methodological weaknesses that constitute the major limitations of most of these studies have been discussed widely. A new generation of approaches is needed to understand the relationship between gene variants and complex kidney transplantation traits. These approaches should be global, to generate original pathophysiological hypotheses, and should rely on advanced genomic tools, including Genome Wide Association studies and Whole Genome Sequencing technologies. Such enterprises will only be successful with the creation of international consortiums that connect partners in clinical, industrial, and academic transplant medicine.


  1. Anglicheau D, Pallet N, Rabant M, Marquet P, Cassinat B, Meria P, Beaune P, Legendre C, Thervet E (2006) Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine–sirolimus interaction. Kidney Int 70:1019–1025PubMedCrossRefGoogle Scholar
  2. Anglicheau D, Legendre C, Beaune P, Thervet E (2007) Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update. Pharmacogenomics 8:835–849PubMedCrossRefGoogle Scholar
  3. Bamoulid J, Courivaud C, Deschamps M, Mercier P, Ferrand C, Penfornis A, Tiberghien P, Chalopin JM, Saas P, Ducloux D (2006) IL-6 promoter polymorphism-174 is associated with new-onset diabetes after transplantation. J Am Soc Nephrol 17:2333–2340PubMedCrossRefGoogle Scholar
  4. Brown KM, Kondeatis E, Vaughan RW, Kon SP, Farmer CK, Taylor JD, He X, Johnston A, Horsfield C, Janssen BJ, Gros P, Zhou W, Sacks SH, Sheerin NS (2006) Influence of donor C3 allotype on late renal-transplantation outcome. N Engl J Med 354:2014–2023PubMedCrossRefGoogle Scholar
  5. Cattaneo D, Ruggenenti P, Baldelli S, Motterlini N, Gotti E, Sandrini S, Salvadori M, Segoloni G, Rigotti P, Donati D, Perico N, Remuzzi G (2009) ABCB1 genotypes predict cyclosporine-related adverse events and kidney allograft outcome. J Am Soc Nephrol 20:1404–1415PubMedCrossRefGoogle Scholar
  6. Choi M, Scholl UI, Ji W, Liu T, Tikhonova IR, Zumbo P, Nayir A, Bakkaloglu A, Ozen S, Sanjad S, Nelson-Williams C, Farhi A, Mane S, Lifton RP (2009) Genetic diagnosis by whole exome capture and massively parallel DNA sequencing. Proc Natl Acad Sci USA 106:19096–19101PubMedCrossRefGoogle Scholar
  7. Cipollone F, Toniato E, Martinotti S, Fazia M, Iezzi A, Cuccurullo C, Pini B, Ursi S, Vitullo G, Averna M, Arca M, Montali A, Campagna F, Ucchino S, Spigonardo F, Taddei S, Virdis A, Ciabattoni G, Notarbartolo A, Cuccurullo F, Mezzetti A (2004) A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke. JAMA 291:2221–2228PubMedCrossRefGoogle Scholar
  8. Cirulli ET, Singh A, Shianna KV, Ge D, Smith JP, Maia JM, Heinzen EL, Goedert JJ, Goldstein DB (2010) Screening the human exome: a comparison of whole genome and whole transcriptome sequencing. Genome Biol 11:R57PubMedGoogle Scholar
  9. Copeland KR, Thliveris JA, Yatscoff RW (1990) Toxicity of cyclosporine metabolites. Ther Drug Monit 12:525–532PubMedCrossRefGoogle Scholar
  10. Coto E, Tavira B (2009) Pharmacogenetics of calcineurin inhibitors in renal transplantation. Transplantation 88:S62–S67PubMedCrossRefGoogle Scholar
  11. Courivaud C, Bamoulid J, Loupy A, Deschamps M, Ferrand C, Le Corre D, Tiberghien P, Chalopin JM, Legendre C, Thervet E, Saas P, Ducloux D (2009a) Influence of cyclooxygenase-2 (COX-2) gene promoter polymorphism-765 on graft loss after renal transplantation. Am J Transplant 9:2752–2757PubMedCrossRefGoogle Scholar
  12. Courivaud C, Bamoulid J, Tiberghien P, Saas P, Chalopin JM, Ducloux D, Legendre C, Thervet E (2009b) G-765C COX-2 gene promoter polymorphism and risk of atherosclerosis after kidney transplantation. Transplantation 88:851–852PubMedCrossRefGoogle Scholar
  13. Ducloux D, Deschamps M, Yannaraki M, Ferrand C, Bamoulid J, Saas P, Kazory A, Chalopin JM, Tiberghien P (2005) Relevance of Toll-like receptor-4 polymorphisms in renal transplantation. Kidney Int 67:2454–2461PubMedCrossRefGoogle Scholar
  14. el-Agroudy AE, Sobh MA, Hamdy AF, Ghoneim MA (2004) A prospective, randomized study of coadministration of ketoconazole and cyclosporine a in kidney transplant recipients: ten-year follow-up. Transplantation 77:1371–1376PubMedCrossRefGoogle Scholar
  15. El-Dahshan KF, Bakr MA, Donia AF, Badr Ael S, Sobh MA (2006) Ketoconazole-tacrolimus coadministration in kidney transplant recipients: two-year results of a prospective randomized study. Am J Nephrol 26:293–298PubMedCrossRefGoogle Scholar
  16. Frazer KA, Murray SS, Schork NJ, Topol EJ (2009) Human genetic variation and its contribution to complex traits. Nat Rev Genet 10:241–251PubMedCrossRefGoogle Scholar
  17. Ghisdal L, Baron C, Le Meur Y, Lionet A, Halimi JM, Rerolle JP, Glowacki F, Lebranchu Y, Drouet M, Noel C, El Housni H, Cochaux P, Wissing KM, Abramowicz D, Abramowicz M (2009) TCF7L2 polymorphism associates with new-onset diabetes after transplantation. J Am Soc Nephrol 20:2459–2467PubMedCrossRefGoogle Scholar
  18. Goldfarb-Rumyantzev AS, Naiman N (2008) Genetic prediction of renal transplant outcome. Curr Opin Nephrol Hypertens 17:573–579PubMedCrossRefGoogle Scholar
  19. Goldfarb-Rumyantzev AS, Naiman N (2010) Genetic predictors of acute renal transplant rejection. Nephrol Dial Transplant 25:1039–1047PubMedCrossRefGoogle Scholar
  20. Grinyo J, Vanrenterghem Y, Nashan B, Vincenti F, Ekberg H, Lindpaintner K, Rashford M, Nasmyth-Miller C, Voulgari A, Spleiss O, Truman M, Essioux L (2008) Association of four DNA polymorphisms with acute rejection after kidney transplantation. Transpl Int 21:879–891PubMedCrossRefGoogle Scholar
  21. Hauser I, Schaeffeler E, Gauer S, Scheuermann E, Wegner B, Gossmann J, Ackermann H, Seidl C, Hocher B, Zaner U, Geiger H, Eichelbaum M, Schwab M (2005) ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J Am Soc Nephrol 16:1501–1511PubMedCrossRefGoogle Scholar
  22. Kang ES, Kim MS, Kim YS, Kim CH, Han SJ, Chun SW, Hur KY, Nam CM, Ahn CW, Cha BS, Kim SI, Lee HC (2008) A polymorphism in the zinc transporter gene SLC30A8 confers resistance against posttransplantation diabetes mellitus in renal allograft recipients. Diabetes 57:1043–1047PubMedCrossRefGoogle Scholar
  23. Kurzawski M, Dziewanowski K, Kedzierska K, Gornik W, Banas A, Drozdzik M (2010) Association of calpain-10 gene polymorphism and posttransplant diabetes mellitus in kidney transplant patients medicated with tacrolimus. Pharmacogenomics J 10:120–125PubMedCrossRefGoogle Scholar
  24. Kuypers DR, de Jonge H, Naesens M, Lerut E, Verbeke K, Vanrenterghem Y (2007) CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin Pharmacol Ther 82:711–725PubMedCrossRefGoogle Scholar
  25. La Manna G, Cappuccilli ML, Cianciolo G, Conte D, Comai G, Carretta E, Scolari MP, Stefoni S (2010) Cardiovascular disease in kidney transplant recipients: the prognostic value of inflammatory cytokine genotypes. Transplantation 89:1001–1008PubMedCrossRefGoogle Scholar
  26. Lee JP, Bae JB, Yang SH, Cha RH, Seong EY, Park YJ, Ha J, Park MH, Paik JH, Kim YS (2011) Genetic predisposition of donors affects the allograft outcome in kidney transplantation; polymorphisms of stromal-derived factor-1 and CXC receptor 4. PLoS One 6:e16710PubMedCrossRefGoogle Scholar
  27. Leite JL, Manfrinatto JA, Mazzali M, Ward LS (2006) Polymorphisms at exon 4 of p53 and the susceptibility to herpesvirus types 6 and 1 infection in renal transplant recipients. Transpl Int 19:732–737PubMedCrossRefGoogle Scholar
  28. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, McCarthy MI, Ramos EM, Cardon LR, Chakravarti A, Cho JH, Guttmacher AE, Kong A, Kruglyak L, Mardis E, Rotimi CN, Slatkin M, Valle D, Whittemore AS, Boehnke M, Clark AG, Eichler EE, Gibson G, Haines JL, Mackay TF, McCarroll SA, Visscher PM (2009) Finding the missing heritability of complex diseases. Nature 461:747–753PubMedCrossRefGoogle Scholar
  29. McLeod HL, Siva C (2002) The thiopurine S-methyltransferase gene locus—implications for clinical pharmacogenomics. Pharmacogenomics 3:89–98PubMedCrossRefGoogle Scholar
  30. Metalidis C, Lerut E, Naesens M, Kuypers DR (2010) Expression of CYP3A5 and P-glycoprotein in renal allografts with histological signs of calcineurin inhibitor nephrotoxicity. Transplantation 91:1098–1102CrossRefGoogle Scholar
  31. Metzker ML (2010) Sequencing technologies—the next generation. Nat Rev Genet 11:31–46PubMedCrossRefGoogle Scholar
  32. Michelon H, Konig J, Durrbach A, Quteineh L, Verstuyft C, Furlan V, Ferlicot S, Letierce A, Charpentier B, Fromm MF, Becquemont L (2010) SLCO1B1 genetic polymorphism influences mycophenolic acid tolerance in renal transplant recipients. Pharmacogenomics 11:1703–1713PubMedCrossRefGoogle Scholar
  33. Moore J, McKnight AJ, Simmonds MJ, Courtney AE, Hanvesakul R, Brand OJ, Briggs D, Ball S, Cockwell P, Patterson CC, Maxwell AP, Gough SC, Borrows R (2010) Association of caveolin-1 gene polymorphism with kidney transplant fibrosis and allograft failure. JAMA 303:1282–1287PubMedCrossRefGoogle Scholar
  34. Ozsolak F, Milos PM (2011) RNA sequencing: advances, challenges and opportunities. Nat Rev Genet 12:87–98PubMedCrossRefGoogle Scholar
  35. Perkins D, Verma M, Park KJ (2011) Advances of genomic science and systems biology in renal transplantation: a review. Semin Immunopathol 33:211–218PubMedCrossRefGoogle Scholar
  36. Reeves-Daniel AM, DePalma JA, Bleyer AJ, Rocco MV, Murea M, Adams PL, Langefeld CD, Bowden DW, Hicks PJ, Stratta RJ, Lin JJ, Kiger DF, Gautreaux MD, Divers J, Freedman BI (2010) The APOL1 gene and allograft survival after kidney transplantation. Am J Transplant 11:1025–1030CrossRefGoogle Scholar
  37. Roby KA, Shaw LM (1993) Effects of cyclosporine and its metabolites in the isolated perfused rat kidney. J Am Soc Nephrol 4:168–177PubMedGoogle Scholar
  38. Soulillou JP, Giral M (2006) Influence of graft characteristics on the outcome of kidney transplantation. N Engl J Med 354:2060–2062PubMedCrossRefGoogle Scholar
  39. Thervet E, Loriot MA, Barbier S, Buchler M, Ficheux M, Choukroun G, Toupance O, Touchard G, Alberti C, Le Pogamp P, Moulin B, Le Meur Y, Heng AE, Subra JF, Beaune P, Legendre C (2010) Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin Pharmacol Ther 87:721–726PubMedGoogle Scholar
  40. Turka LA, Wood K, Bluestone JA (2010) Bringing transplantation tolerance into the clinic: lessons from the ITN and RISET for the Establishment of Tolerance consortia. Curr Opin Organ Transplant 15:441–448PubMedCrossRefGoogle Scholar
  41. Vanrenterghem YF, Claes K, Montagnino G, Fieuws S, Maes B, Villa M, Ponticelli C (2008) Risk factors for cardiovascular events after successful renal transplantation. Transplantation 85:209–216PubMedCrossRefGoogle Scholar
  42. Varagunam M, Yaqoob MM, Dohler B, Opelz G (2009) C3 polymorphisms and allograft outcome in renal transplantation. N Engl J Med 360:874–880PubMedCrossRefGoogle Scholar
  43. Wahrmann M, Dohler B, Ruhenstroth A, Haslacher H, Perkmann T, Exner M, Rees AJ, Bohmig GA (2011) Genotypic diversity of complement component C4 does not predict kidney transplant outcome. J Am Soc Nephrol 22:367–376PubMedCrossRefGoogle Scholar
  44. Wang J, Yang JW, Zeevi A, Webber SA, Girnita DM, Selby R, Fu J, Shah T, Pravica V, Hutchinson IV, Burckart GJ (2008) IMPDH1 gene polymorphisms and association with acute rejection in renal transplant patients. Clin Pharmacol Ther 83:711–717PubMedCrossRefGoogle Scholar
  45. Weber LT, Hoecker B, Armstrong VW, Oellerich M, Tonshoff B (2008) Long-term pharmacokinetics of mycophenolic acid in pediatric renal transplant recipients over 3 years posttransplant. Ther Drug Monit 30:570–575PubMedCrossRefGoogle Scholar
  46. Werner T (2010) Next generation sequencing in functional genomics. Brief Bioinform 11:499–511PubMedCrossRefGoogle Scholar
  47. Woillard JB, Rerolle JP, Picard N, Rousseau A, Guillaudeau A, Munteanu E, Essig M, Drouet M, Le Meur Y, Marquet P (2010) Donor P-gp polymorphisms strongly influence renal function and graft loss in a cohort of renal transplant recipients on cyclosporine therapy in a long-term follow-up. Clin Pharmacol Ther 88:95–100PubMedCrossRefGoogle Scholar
  48. Yang J, Hutchinson II, Shah T, Min DI (2011) Genetic and clinical risk factors of new-onset diabetes after transplantation in Hispanic kidney transplant recipients. Transplantation 91:1114–1119PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  1. 1.INSERM U775, Centre Universitaire des Saints PèresUniversité Paris DescartesParisFrance
  2. 2.Service de Néphrologie, Hôpital Européen Georges PompidouUniversité Paris DescartesParisFrance

Personalised recommendations